obstructive-sleep-apnea
(2)
David Weber
David Weber, PhD, is the President and CEO of Mosanna Therapeutics, a Redwood City biotech developing MOS118, a bedtime nasal spray for obstructive sleep apnea that aims to restore the body's natural airway reflex during sleep. A biotech operator with more than 30 years in drug development, capital formation, and corporate strategy, he previously led Otonomy through its IPO and multiple clinical programs, and served as CEO of MacuSight and Oculex Pharmaceuticals. He joined Mosanna in June 2025 as the company launched with an $80 million Series A.
Peter Martin
Peter Martin is the co-founder, President and CEO of Siesta Medical, a Los Gatos medical device company building minimally invasive treatments for obstructive sleep apnea that need no masks and no machines. Since 2009 he has guided the company from an idea to FDA-cleared products - the Encore System, the Revolution Suture Passer and the AIRLIFT hyoid suspension procedure - that reposition the airway with two small implants and a stitch. A Duke and Stanford trained mechanical engineer, he spent 15-plus years in medical device operations before turning Siesta into one of the most-cited names in surgical sleep apnea care.